What question did this study set out to answer?

The trial aims to assess the effectiveness and safety of IO102-IO103 combined with nivolumab-relatlimab in treating unresectable melanoma.

A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma.

View Full Paper

Ask AI

Bookmark

The trial aims to assess the effectiveness and safety of IO102-IO103 combined with nivolumab-relatlimab in treating unresectable melanoma.
Multicenter phase 2 trial (NCT05912244)
Treated 43 patients with unresectable non-uveal melanoma using IO102-IO103 and nivo-rela for up to two years
Evaluated best overall response rate (BORR) and progression-free survival (PFS) using RECIST v1.1 and Kaplan-Meier methods.
BORR was 60% (95% CI: 44-75%) with 19 partial responses and 7 complete responses.
Median PFS was 8.2 months (95% CI 6.8, NR) with similar rates for PD-L1 negative tumors.
21% of patients experienced grade 3-4 treatment-related adverse events, but no treatment-related deaths were reported.

No takes yet. Share an insight, caveat, or question.

Randomized trial investigates IO102-IO103 and nivo-rela combination for melanoma, suggesting improved outcomes.

Smithy et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark